

Early View

Research letter

COVID-19 in patients with Pulmonary Alveolar Proteinosis A European multicenter study

Spyros A. Papiris, Ilaria Campo, Francesca Mariani, Maria Kallieri, Lykourgos Kolilekas, Andriana I Papaioannou, Efsun Gonca Chousein, Erdogan Cetinkaya, Francesco Bonella, Raphael Borie, Maria Kokosi, Thomas Pickworth, Maria Molina-Molina, Mercè Gasa, Elżbieta Radzikowska, Justyna Fijolek, Stéphane Jouneau, Emmanuel Gomez, Cormac McCarthy, Elisabeth Bendstrup, Wojciech J. Piotrowski, Rishi Pabary, Alice Hadchouel, Nathalie Coolen-Allou, Tiago Alfaro, Carlos Robalo Cordeiro, Elvira-Markela Antonogiannaki, Ioannis P. Tomos, Despoina Papakosta, Theodoros Kontakiotis, Panagiota Panagiotou, Konstantinos Douros, Andrea Schams, Sara Lettieri, Vassiliki Papaevangelou, Christina Kanaka-Gantenbein, Anna Karakatsani, Stelios Loukides, Ulrich Costabel, Bruno Crestani, Cliff Morgan, Ryushi Tazawa, Andrew Bush, Matthias Griesse, Effrosyni D. Manali

Please cite this article as: Papiris SA, Campo I, Mariani F, *et al.* COVID-19 in patients with Pulmonary Alveolar Proteinosis A European multicenter study. *ERJ Open Res* 2022; in press (<https://doi.org/10.1183/23120541.00199-2022>).

This manuscript has recently been accepted for publication in the *ERJ Open Research*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

COVID-19 in patients with Pulmonary Alveolar Proteinosis

A European multicenter study

Spyros A. Papiris¹, Ilaria Campo², Francesca Mariani², Maria Kallieri¹, Lykourgos Kolilekas³, Andriana I Papaioannou¹, Efsun Gonca Chousein⁴, Erdogan Cetinkaya⁴, Francesco Bonella⁵, Raphael Borie⁶, Maria Kokosi⁷, Thomas Pickworth⁸, Maria Molina-Molina⁹, Mercè Gasà⁹, Elżbieta Radzikowska¹⁰, Justyna Fijolek¹⁰, Stéphane Jouneau¹¹, Emmanuel Gomez¹², Cormac McCarthy¹³, Elisabeth Bendstrup¹⁴, Wojciech J. Piotrowski¹⁵, Rishi Pabary¹⁶, Alice Hadchouel¹⁷, Nathalie Coolen-Allou¹⁸, Tiago Alfaro¹⁹, Carlos Robalo Cordeiro¹⁹, Elvira-Markela Antonogiannaki¹, Ioannis P. Tomos¹, Despoina Papakosta²⁰, Theodoros Kontakiotis²⁰, Panagiota Panagiotou²¹, Konstantinos Douros²², Andrea Schams²³, Sara Lettieri², Vassiliki Papaevangelou²², Christina Kanaka-Gantenbein²¹, Anna Karakatsani¹, Stelios Loukides¹, Ulrich Costabel⁵, Bruno Crestani⁶, Cliff Morgan⁷, Ryushi Tazawa²⁴, Andrew Bush¹⁶, Matthias Griesse²³, Effrosyni D. Manali¹.

¹ General University Hospital "Attikon", Medical School, National and Kapodistrian University of Athens, Greece, papiris@otenet.gr, mkallieri@yahoo.gr, kantonogiannaki@gmail.com, etomos@hotmail.com, papaioannouandriana@gmail.com, akarakats@med.uoa.gr, loukstel@med.uoa.gr, fmanali@otenet.gr

² Laboratorio di Biochimica e Genetica, U.O.C. Pneumologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, I.Campo@smatteo.pv.it, fr.mariani@smatteo.pv.it, sara.letteri01@universitadipavia.it

³ Dr Lykourgos Kolilekas, 7th Pulmonary Department, Athens Chest Hospital "Sotiria", Athens Greece, lykol@yahoo.gr

⁴ University of Health Sciences Turkey, Yedikule Chest Diseases and Thoracic Surgery Research and Training Hospital, İstanbul, Turkey, efsungoncachousein@yahoo.com, erdogan.cetinkaya@sbu.edu.tr, ecetinkaya34@yahoo.com

⁵ Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University Hospital, University of Essen, Essen, Germany; European Reference Network (ERN)-LUNG, ILD Core Net, Francesco.Bonella@rlk.uk-essen.de, ulrich.costabel@rlk.uk-essen.de

⁶ Université de Paris, INSERM UMR 1152, Paris, France, APHP, Hôpital Bichat, Service de Pneumologie A, FHU APOLLO, Centre de référence des maladies pulmonaires rares, Paris, France, raphael.borie@aphp.fr, bruno.crestani@aphp.fr

⁷ Interstitial Lung Disease Unit, Royal Brompton Hospital & Harefield NHS Foundation Trust, London SW3 6NP, UK; Interstitial Lung Disease Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK. m.kokosi@rbht.nhs.uk, cliffmorgan@blueyonder.co.uk

⁸ Department of Anaesthesia, Royal Brompton Hospital, London, UK. T.Pickworth@rbht.nhs.uk

- ⁹ ILD Multidisciplinary Unit Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain. mariamolinamolina@hotmail.com, mgasa@bellvitgehospital.cat
- ¹⁰ 3rd Department of Lung Diseases and Oncology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland, e.radzikowska@wp.pl, ifijolek@op.pl
- ¹¹ IRSET UMR 1085, Université de Rennes Service de Pneumologie, CHU de Rennes, France, Stephane.JOUNEAU@chu-rennes.fr
- ¹² Pneumologie, CHU de Nancy, e.gomez@chru-nancy.fr
- ¹³ University College Dublin School of Medicine Education and Research Centre, St. Vincent's University Hospital, Dublin 4, Ireland, cormac.mccarthy@ucd.ie
- ¹⁴ Center for Rare Lung diseases, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Denmark, karbends@rm.dk
- ¹⁵ Department of Pneumology, 2nd Chair of Internal Medicine, Medical University of Lodz, Lodz, wojciech.piotrowski@umed.lodz.pl
- ¹⁶ Paediatrics and Paediatric Respiriology, Imperial College, UK; Imperial Centre for Paediatrics and Child Health, UK, Royal Brompton Harefield NHS Foundation Trust, London, UK, .a.bush@imperial.ac.uk, A.Bush@rbht.nhs.uk, R.Pabary@rbht.nhs.uk
- ¹⁷ AP-HP, Hôpital Necker-Enfants Malades, Service de Pneumologie Pédiatrique, Centre de Référence pour les Maladies Respiratoires Rares de l'Enfant, Paris, France, INSERM U1151, Institut Necker Enfants Malades, Paris, France, Université de Paris, Faculté de Médecine, Paris, France, alice.hadchouel-duverge@aphp.fr
- ¹⁸ Service de Pneumologie Hôpital Félix Guyon, CHU Réunion, nathalie.allou@chu-reunion.fr
- ¹⁹ Department of Pulmonology, Coimbra Univesrity Hospital, Univesrity of Coimbra, Portugal, alfarotm@gmail.com, carlos.crobalo@gmail.com
- ²⁰ A Department of Pulmonary Medicine, Aristotle University of Thessaloniki, "G. Papanikolaou" Hospital, Exochi, Thessaloniki, Greece dpapakos@med.auth.gr, kontakiotis@gmail.com,
- ²¹ First Department of Paediatrics, Agia Sophia Children's Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece, panagpan@med.uoa.gr, chriskan@med.uoa.gr
- ²² Third Department of Pediatrics "Attikon" University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece, costasdouros@gmail.com, vpapaev@med.uoa.gr
- ²³ Department of Pediatric Pneumology, Dr von Hauner Children's Hospital, Ludwig-Maximilians-University, German Center for Lung Research, Munich, Germany matthias.griese@med.uni-muenchen.de, Andrea.Schams@med.uni-muenchen.de

²⁴ Health Administration Center, Tokyo Medical and Dental University, Tokyo, Japan, ryushi.hsc@tmd.ac.jp

Author's contributions: SAP had major contribution to the concept and design of the study, to the acquisition, analysis and interpretation of data, had access to all data and wrote the manuscript with EDM; IC, FM, MK, LK had major contribution to the acquisition and interpretation of data for the work and revised critically this work for important intellectual content; AIP performed the statistical analysis of the data, contributed substantially to the interpretation of data for the work and drafted part of the manuscript; ECH, EC, FB, RB, MK, TP, MMM, MG, ER, JF, SJ, EG, CMcC, EB, WJP, RP, AH, NC-A, TA, CRC, EMA, IPT, DP, TK, PP, KD, AS, SL, VP, CKG, AK, SL, UC, BC, CM, AB, MG had major contribution to the acquisition and interpretation of data for the work and revised critically this work for important intellectual content; RT contributed in interpreting the data and revised critically this work for important intellectual content. EDM had major contribution to the concept and design of the study, to the acquisition, analysis and interpretation of data, had access to all data, supervised the accuracy and integrity of any part of the work and wrote the manuscript with SAP. All authors read and approved of the final version of the submitted publication.

Take home message

Adult PAP patients experienced similar COVID-19 rates with the general population and high rates of hospitalizations and deaths underscoring their vulnerability and the need for measures to prevent infection. The impact of iGM-CSF must be considered.

Key words: pulmonary alveolar proteinosis; COVID-19; adults; children; i-GM-CSF; outcome

Introduction

Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) signaling is essential in both alveolar macrophages (AMs) differentiation and activation of lung immune cells [1]. Differentiated AMs are crucial in both the elimination of alveolar microbes and surfactant clearance. The disruption of the GM-CSF axis in alveolar macrophages leads to the development of pulmonary alveolar proteinosis (PAP) [1]. In the majority of patients this relates to the presence of autoantibodies against GM-CSF autoimmune (a)PAP but there are multiple other causes [1, 2, 3]. GM-CSF deficient animals may have impaired lung inflammatory response to commensal microbes and humans with PAP may occasionally develop opportunistic lung infections [4]. The mainstay of pharmacological treatment in aPAP is inhaled GM-CSF which is off-label but increasingly used worldwide [5, 6, 7 8, 9].

Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), a new infection causing COVID-19 is clearly associated with worse prognosis in adults with preexisting lung disorders and might represent an additional risk factor for severe pneumonia in PAP patients [10, 11]. However, controversy exists regarding the relationship between GM-CSF signaling and outcome of COVID-19 [12] [Figure 1]. There are no studies in patients with PAP who also have COVID-19. We hypothesized that patients with PAP would be at increased risk and have poor outcomes. This European collaborative study aimed to investigate prevalence and clinical consequences of COVID-19 in PAP patients and the impact of prior iGM-CSF treatment on outcome.

Methods

This multi-center, observational, retrospective, European collaborative study includes all adult and pediatric PAP patients with COVID-19 diagnosed in referral centers from 11 European Countries from January 24th 2020 to August 31st 2021. PAP diagnosis was based on chest computerized tomography (CT) findings and the results of either lung biopsy or cytologic analysis of bronchoalveolar lavage (BAL) fluid. Further characterization of autoimmune or hereditary PAP was based on increased levels of GM-CSF autoantibodies or a positive genetic analysis for CSF2RA, CSF2RB or MARS mutations respectively [1]. PAP patients were eligible if COVID-19 was confirmed either by RT-PCR or by compatible clinical (acute onset of fever, flu-like symptoms, headache, and anosmia), radiological and serology findings [10]. Generally, hospitalization was considered in patients with dyspnea or increased respiratory rate (≥ 30 breaths per min), or oxygen saturation $\leq 94\%$ on room air or decrease in saturation to $< 90\%$ with ambulation and also on the basis of overall clinical concern by Emergency Department staff, including perceived risk of high risk for complications from severe COVID-19". [<https://www.bumc.bu.edu/id/covid-19-response/clinical-algorithms-for-admission-and-discharge/>]. The prevalence of COVID-19 in PAP patients was calculated and demographic, clinical and functional characteristics closest to the time of COVID-19 infection as well as outcomes were collected using anonymized data forms. Since the prevalence of COVID-19 has differed between countries during the pandemic, the median prevalence (IQR) of COVID-19 in all European countries participating in the study was calculated at 14.8% (11.09-17.15), taking into consideration the population of each country and the cumulative cases of COVID-19 officially

reported [<https://www.ecdc.europa.eu/en/covid-19/data>] (footnote Table 1). The study was approved by all the Medical Ethics Committees, first that of the General University Hospital “Attikon”, Athens, Greece (BΠNEYM, EΒΔ657/30-11-2021).

Statistical Analysis

Normality of distributions was checked with Kolmogorov-Smirnov test. Categorical variables are presented as n (%), whereas numerical variables are presented as median (interquartile ranges) or as mean (minimum, maximum value) for the results in the adult and children population respectively. Comparisons between groups were performed using chi-square tests for categorical data and Mann-Whitney U test for numerical data. Cox regression univariate and multivariate analyses were performed to evaluate predictors of outcome. Data were analyzed using SPSS 18.0 for Windows (SPSS Inc, Chicago, IL, USA), p-values <0.05 were considered statistically significant.

Results

COVID-19 infection was diagnosed in 34 out of 255 PAP patients (13.3%), 31/34 were adults (91.2%), 30/31 with aPAP, 19/31 (61.3%) male, median age at inclusion (IQR) 47 years (35-56), median disease duration 57 (35-115) months, ever-smokers 61.3%, FVC% 78 (64.3-86), DLCO% 62.9 (48.8-70.75) of predicted, long-term oxygen therapy (LTOT) 7/31 (22.6%). Whole lung lavage (WLL) had been performed in 27/31 (87.1%) and iGM-CSF prescribed in 15 (48.4%) (Table 1).

In aPAP patients COVID-19 presented mostly with fever (77.4%) and dyspnea (61.3%). All patients were infected before the preventive option of vaccination was available. 11/31 patients (35.5%) needed hospitalization, 5/31 patients (16.1%) in the ICU. All patients with mild disease treated at home survived. Among hospitalized patients, two died and one patient underwent lung transplantation (3/11, 27%). These three patients had worse DLCO% predicted ($p=0.019$) and had more often arterial hypertension (AH) ($p=0.012$) and a smoking history ($p=0.002$). Treatment with iGM-CSF was withheld during hospitalization in all patients. Gender, age, disease duration, spirometry results, LTOT, comorbidities, history of WLL and of iGM-CSF treatment had no impact upon hospitalization or outcome. Among seven children (5 hereditary PAP), 3 developed COVID-19 (2 hereditary PAP), all needed hospitalization and all survived (Table 1).

Discussion

To our knowledge this is the only study of COVID-19 disease in PAP. The major findings are: 1) COVID-19 developed in 13.3% of patients, the majority were adults (91.2%), all with aPAP, all unvaccinated, 2) one third needed hospitalization (35.5%), almost fifty percent in the ICU 3) although the numbers are small, 27% hospitalized patients either died or were lung-transplanted, whereas all patients with mild disease treated at home survived 4) poor prognosis was related to lower DLCO% predicted, AH and smoking history, 5) previous treatment with iGM-CSF had no impact upon hospitalization or outcome 6) all pediatric patients were hospitalized but survived.

The prevalence of COVID-19 in PAP patients was found to be similar to the calculated median prevalence of COVID-19 in the general population of participating European Countries (13.3% vs 14.8%, $p=0.256$). However, previous studies demonstrated that other groups of ILD experienced lower than expected COVID-19 most probably due to better use of prophylactic measures and remote contact with physicians for electronic prescription of treatment [13]. The younger age of PAP patients and presumably their higher sociability might partly explain discrepancy.

During the pandemic it soon became clear that adults with chronic respiratory diseases, especially ILD, were at increased risk of developing severe COVID-19 and dying [10, 11]. There are very few data regarding COVID-19 and ultra-rare diffuse parenchymal lung diseases. Lymphangioleiomyomatosis (LAM) patients with COVID-19, compared to an age-matched general population (30-59 years), had increased rates of hospitalization but not mortality [14]. In the present study, PAP patients showed increased rates of mortality and lung transplantation, however similar to the upper limits of in-hospital mortality ranges recently reported for certain European Countries [15]. This could be explained by the presence of known risk factors such as AH and smoking and possibly also due to macrophage immunosuppression in PAP [4, 10]. It is known that GM-CSF facilitates AMs and other immune cells to clearance of pathogens including viruses. Based on positive results from animal models, recombinant forms of iGM-CSF are under investigation in patients with COVID-19-related acute hypoxic respiratory failure (NCT04326920). Conversely, inhibition of GM-CSF pathways could reduce the exuberant lung

inflammation in COVID-19. This study cannot distinguish between these possibilities.

Only a small number of children were included in the study because of the rarity of pediatric PAP [3]; half of the patients were COVID-19 with good outcome. The effects of COVID-19 on children are less severe than in adults, but the effects on children with chronic rare respiratory diseases is unknown [16].

The present study has limitations. The number of PAP patients with COVID-19 might be underestimated because asymptomatic or newly diagnosed patients could have been missed; however, the close contact of patients with this ultra-rare disease with specialized centers means that it is likely that at least all patients with a known diagnosis were included. Multivariate analysis was not performed to investigate predictors of mortality because univariate analysis did not demonstrate any significant association probably due to the limited number of patients and events. Finally, the level of enforcement of prophylactic measures may have varied between countries, and the effects of this on the interpretation of the data is challenging and beyond the scope of the present study. However, this collaboration permitted the analysis of data of multiple specialized centers for both children and adults providing a unique opportunity for examining COVID-19 in this ultra-rare disease.

In conclusion, PAP patients experienced similar rates of COVID-19 with the general population and high rates of hospitalizations and deaths, underscoring the vulnerability of this population and the necessity of

preventive measures to avoid infection. If infected, secondary prophylaxis with monoclonal antibodies and the impact of iGM-CSF must be considered.

Table 1. Demographic, clinical, functional characteristics and outcomes of patients with PAP who had COVID-19 (n=34) *

Demographic and clinical data for PAP adults who had COVID-19 (n=31)				
<i>Parameter</i>	<i>All (n=31)</i>	<i>Non-Hospitalized (n=20)</i>	<i>Hospitalized (n=11)</i>	<i>p-value</i>
Gender (Male, n%)	19 (61.3)	12 (60.0)	7 (63.6)	p=0.700
Age at inclusion, years	47 (35.0-56.0)	40 (28.5-50.7)	51 (45.0-56.0)	p=0.060
Duration of disease, months	57 (36.0-115.0)	74.5 (38.0-127.5)	43 (28.0-98.0)	p=0.256
Autoimmune PAP, n (%) ***	30 (96.8)	19 (95)	11 (100)	p=0.451
GM-CSF autoantibody level (mcg/ml)	89.5 (52.3-154.7)	69.01 (21.1-187.7)	107.6 (62.3-125.2)	p=0.625
PAP documented by lung biopsy, n (%)	9 (29)	3 (15)	6 (54.5)	p=0.020
Smoking (no/yes/ex), (%)	38.7/9.7/51.6	45/5/50	27.3/18.2/54.5	p=0.391
BMI	26.9 (23.5-30.0)	26.9 (23.4-29.3)	27 (22.6-34.0)	p=0.714
LTOT, n (%)	7 (22.6)	2 (10)	5 (45.5)	p=0.029
Arterial hypertension, n (%)	8 (25.8)	2 (10)	6 (54.5)	p=0.007
History of treatment with WLL, n (%)	27 (87.1)	18 (90)	9 (81.8)	p> 0.950
Number of WLL	2 (1-4)	2 (1-3)	3 (1-11)	p=0.283
History of treatment with iGM-CSF, n (%)	15 (48.4)	10 (50)	5 (45.5)	p=0.809
FVC % predicted	78 (64.3-86.0)	81.5 (71.0-89.0)	73 (55.0-81.0)	p=0.175
DLCO % predicted	62.9 (48.8-70.7)	69.4 (53.0-75.5)	53 (35.5-69.3)	p=0.137
SpO ₂ % at rest	96.0 (95.5-98)	97.0 (94.0-98.0)	95.5 (94.5-96.2)	p=0.257
Distance walked at 6MWT, meters	481 (360-525)	501 (437.5-560.0)	407 (333.7-483.3)	p=0.060
Fever, n (%)	24 (77.4)	14 (70)	10 (90.9)	p=0.053
Dyspnea, n (%)	19 (61.3)	10 (50)	9 (81.8)	p=0.032
Fatigue, n (%)	18 (58.1)	10 (50)	8 (72.7)	p=0.114
Cough, n (%)	16 (51.6)	8 (40)	8 (72.7)	p=0.038
Anosmia, n (%)	9 (29)	6 (30)	3 (27.3)	p>0.950
Oxygen therapy or increase of oxygen	11 (35.5)	0 (0)	11 (100)	p<0.001
HFNC	7 (22.6)	0 (0)	7 (63.6)	p<0.001
Corticosteroids systemic	18 (58.1)	8 (40)	11 (100)	p=0.001

Macrolides	14 (45.2)	6 (30)	8 (72.3)	p=0.031
Anticoagulants	13 (40)	4 (20)	9 (81.8)	p=0.020
Remdesivir	2 (6.4)	0 (0)	2 (18.2)	p=0.118
Other (Plasma therapy, Bamlavinmab)	2 (6.4)	0 (0)	2 (18.2)	p=0.118
iGM-CSF	2 (6.4)	2 (10)	0 (0)	p=0.527
ICU admission, n (%)	5 (16.1)	0 (0)	5 (45.5)	p=0.003
Death or lung transplantation, n (%)	3 (9.7)	0 (0)	3 (27.3)	p=0.037

Demographic and clinical data for children who had PAP (n=7)

<i>Parameter</i>	<i>All (n=7)</i>	<i>Without COVID-19 (n=4)</i>	<i>With COVID-19 (n=3)</i>	<i>p-value</i>
Gender, male (%)	4 (57.1)	1 (25)	3 (100)	p=0.100
Age at inclusion, years	12 (5-17)	6 (11-17)	9 (5-14)	p=0.108
Duration of disease, months	33 (3-36)	23 (3-26)	22 (14-36)	p=0.154
Autoimmune PAP, n (%)	2 (28.6)	1 (25)	1 (33.3)	p=0.809
Congenital PAP ***, n (%)	5 (71.4)	3 (75)	2 (66.7)	p=0.809
BMI [kg/m ²]	13.1 (14.4-27.5)	13.1 (14.4 (27.5)	7 (14.6-21.6)	p=0.724
LTOT, n (%)	5 (71.4)	3 (75)	2 (66.7)	p=0.809
History of treatment with WLL, n (%)	5 (71.4)	3 (75)	2 (66.7)	p=0.809
Number of WLL	96 (0-96)	96 (0-96)	13 (0-13)	p=0.372
History of treatment with iGM-CSF, n (%)	1 (14.3)	1 (25)	0 (0)	p=0.325
Other (Methionine, AZM, simvastatin, bromhexine)	5 (71.4)	3 (75)	2 (66.7)	p>0.950
FVC % predicted	47 (35-82)	19 (39-58)	47 (35-82)	p>0.950
DLCO % predicted	61 (31-92)	18 (31-49)	0 (92)	p=0.221
SpO ₂ % at rest	22 (75-97)	22 (75-97)	12 (85-97)	p>0.950
Hospitalization****, n (%)	3 (42.9)		3 (100)	
Death or lung transplantation	0 (0)		0 (0)	

* 21/31 adult patients had SARS-CoV-2 infection documented by RT-PCR, only 1 adult patient had received one dose of the vaccine against SARS-CoV-2 before developing COVID-19, 3/3 children had SARS-CoV-2 infection documented by RT-PCR

** The median prevalence (IQR) of COVID-19 for European countries participating in the study was calculated taking into consideration the population of each country and the cumulative cases of COVID-19 officially reported for each one as per January 7th, 2022 and was found 14.8% (11.09-17.15) [<https://www.ecdc.europa.eu/en/covid-19/data>], in detail: Greece 14.02%, Italy 11.74%, Germany 8.85%, Denmark 15.68%, France 17.14%, Turkey 10.81%, Poland 11.09%, Spain 14.8%, Ireland 18.13%, United Kingdom 20.74%, Portugal 15.15%). Regarding adult PAP patients the prevalence was calculated by COVID-19 patients /Active PAP patients followed-up in each center (Italy, 10/50, Greece 3/27, Turkey 3/11, Poland 3/9, Germany 2/38, France 3/38, Spain 2/9, United Kingdom 2/50, Denmark 1/10, Ireland 1/4 Portugal 1/2: 31/255=12.5%. Children included in the study were as follows: 4 in Germany, 1 in the United Kingdom, 1 in France and 1 in Greece; 3 children (Germany) presented COVID-19. Overall prevalence: 34/255=13.3%.


*** In adults, only one patient had disease related to *CSF2RA* mutation; in children, 1 had disease related to *CSF2RA* (Granulocyte-Macrophage colony-stimulating factor receptor subunit alpha) mutation, 1 related to *CSF2RB* (Granulocyte-Macrophage colony-stimulating factor receptor subunit beta) mutation and 3 to *MARS1*, out of them, 2 brothers with *MARS1* mutation contracted SARS-CoV-2 infection **** details on treatment upon hospitalization are available for 1 child and included HFNC oxygen treatment, systemic corticosteroids, anticoagulants, no iGM-CSF

For adults, values are presented as median (IQR) unless otherwise indicated; for children values are presented as range (minimum-maximum) unless otherwise indicated; IQR= interquartile range; p-values <0.05 were considered statistically significant, PAP: pulmonary alveolar proteinosis; GM-CSF=Granulocyte-Macrophage colony stimulating factor; BMI= Body Mass Index; LTOT=Long-term oxygen therapy; WLL= Whole lung lavage; SpO₂ = Arterial Oxygen Saturation; 6MWT=6minute walking test; COVID-19=Corona Virus Disease 2019; HFNC=High Flow Nasal Canula; ICU=Intensive Care Unit; MARS= methionyl-transfer-RNA-synthetase; M=male; FVC= forced vital capacity; DLCO= diffusing capacity of the lung for carbon monoxide.

Figure legend

Figure 1. Potential relationship between GM-CSF signaling and the early and late inflammatory response to COVID-19.

References



- 1 Trapnell BC, Nakata K, Bonella F, et al. Pulmonary alveolar proteinosis. Nat Rev Dis Primers. 2019; 5:16.
- 2 Hadchouel A, Wieland T, Griese M, et al. Biallelic Mutations of Methionyl-tRNA Synthetase Cause a Specific Type of Pulmonary Alveolar Proteinosis Prevalent on Réunion Island. Am J Hum Genet. 2015; 96:826-831.
- 3 Bush A, Pabary R. Pulmonary alveolar proteinosis in children. Breathe (Sheff). 2020;16:200001.
- 4 Tazawa R, Hamano E, Arai T, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2005; 171:1142-1149.

-
- 5 Tazawa R, Trapnell BC, Inoue Y, et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis Am J Respir Crit Care Med. 2010;181:1345-1354.
 - 6 Papiris SA, Tsirigotis P, Kolilekas L, et al. Long-term inhaled Granulocyte Macrophage-Colony Stimulating Factor in Autoimmune Pulmonary Alveolar Proteinosis: Effectiveness, safety, lowest-effective dose. Clin Drug Invest 2014; 34: 553-564.
 - 7 Papiris SA, Tsirigotis P, Kolilekas L, et al. Pulmonary alveolar proteinosis: time to shift? Expert Rev Respir Med. 2015; 9 :337-349.
 - 8 Tazawa R, Ueda T, Abe M, et al. Inhaled GM-CSF for Pulmonary Alveolar Proteinosis. N Engl J Med. 2019 ;381 :923-932.
 - 9 Trapnell BC, Inoue Y, Bonella F, et al ; IMPALA Trial Investigators. Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis. N Engl J Med. 2020; 383:1635-1644.
 - 10 Gallay L, Uzunhan Y, Borie R, et al. Risk Factors for Mortality after COVID-19 in Patients with Preexisting Interstitial Lung Disease. Am J Respir Crit Care Med. 2021; 203:245-249.
 - 11 Beltramo G, Cottenet J, Mariet AS, et al. Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalized patients: a nationwide study. Eur Respir J. 2021 ; 58 :2004474.
 - 12 Bonaventura A, Vecchié A, Wang TS, et al. Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies. Front Immunol. 2020; 11:1625
 - 13 Papiris SA, Bouros D, Markopoulou K, et al. Early COVID-19 lockdown in Greece and idiopathic pulmonary fibrosis: a beneficial "impact" beyond any expectation. Eur Respir J. 2021 ; 57 :2003111.

14 Baldi BG, Radzikowska E, Cottin V et al. COVID-19 in lymphangioleiomyomatosis: an international study of outcomes and impact of mTOR inhibition. *Chest*. 2021: S0012-3692(21)05166-7.

15 Gray WK, Navaratnam AV, Day J, et al. COVID-19 hospital activity and in-hospital mortality during the first and second waves of the pandemic in England: an observational study. *Thorax*. 2021 Nov 24:thoraxjnl-2021-218025. doi: 10.1136/thoraxjnl-2021-218025]

16 Rasmussen SA, Thompson LA. Coronavirus Disease 2019 and Children: What Pediatric Health Care Clinicians Need to Know *JAMA Pediatr*. 2020; 174:743-744.